Non-invasive genotyping and grading of glioma using advanced MR imaging, histopathology and AI: the iGENE2.0 study

Non-invasive genotyping and grading of glioma using advanced MR imaging, histopathology and AI: the iGENE2.0 study - iGENE2.0

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57298

Enrollment

100

Registered

2025-02-17

Start date

2025-03-31

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced imaging in brain tumors

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Participant must be an adult (18 years or older) Participant must be scheduled for surgery (resection or biopsy) of a (presumed) primary brain tumour Participant must give written informed consent conform ICH-GCP

Exclusion criteria

Exclusion criteria: Contra-indication for MRI (implanted metal parts, e.g. stents, vascular clips, pacemakers, claustrophobia) Inability to give consent Having received/receiving chemotherapy for a brain tumour at time of MRI, prior to surgery

Design outcomes

Primary

Measure	Time frame
The primary study parameter is the diagnostic accuracy with which we can predict glioma genotype, based on pre-operative advanced MRI techniques in combination with our previously developed PrognosAIs algorithm.	—

Secondary

Measure	Time frame
The secondary parameter is the association between MRI signal and tissue features (both at the cellular and molecular level).	—

Countries

Netherlands

Outcome results